1,254 results on '"Rosen, Neal"'
Search Results
2. Impaired proteolysis of non-canonical RAS proteins drives clonal hematopoietic transformation
3. Concurrent SOS1 and MEK suppression inhibits signaling and growth of NF1-null melanoma
4. ARAF protein kinase activates RAS by antagonizing its binding to RASGAP NF1
5. The sixth international RASopathies symposium: Precision medicine-From promise to practice.
6. Anatomic position determines oncogenic specificity in melanoma
7. eIF4A controls translation of estrogen receptor alpha and is a therapeutic target in advanced breast cancer
8. A next-generation BRAF inhibitor overcomes resistance to BRAF inhibition in patients with BRAF-mutant cancers using pharmacokinetics-informed dose escalation
9. Selective inhibitors of mTORC1 activate 4EBP1 and suppress tumor growth
10. Targeted drug delivery strategies for precision medicines
11. Abstract B089: Oncogenic signaling and responses to treatment in RAS mutant cancers are mutation-specific
12. Defining the therapeutic selective dependencies for distinct subtypes of PI3K pathway-altered prostate cancers
13. Anti-tumor effects of an ID antagonist with no observed acquired resistance
14. HER2 + breast cancers evade anti-HER2 therapy via a switch in driver pathway
15. Mutant-selective degradation by BRAF-targeting PROTACs
16. AXL Mediates Resistance to PI3Kα Inhibition by Activating the EGFR/PKC/mTOR Axis in Head and Neck and Esophageal Squamous Cell Carcinomas
17. Acquired BRAF Rearrangements Induce Secondary Resistance to EGFR therapy in EGFR-Mutated Lung Cancers
18. Loss of NF1 in Cutaneous Melanoma Is Associated with RAS Activation and MEK Dependence
19. ERK Activation by BRAFV600E suppresses mesenchymal migration and tumorigenesis by inhibiting RAC1.
20. Efficacy of MEK inhibition in patients with histiocytic neoplasms
21. RAF inhibitor PLX8394 selectively disrupts BRAF dimers and RAS-independent BRAF-mutant-driven signaling
22. RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)
23. RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF
24. Supplementary Table 1 from Molecular Characterization of Acquired Resistance to KRASG12C–EGFR Inhibition in Colorectal Cancer
25. Supplementary Table 2 from Molecular Characterization of Acquired Resistance to KRASG12C–EGFR Inhibition in Colorectal Cancer
26. Supplementary Figure 6 from Molecular Characterization of Acquired Resistance to KRASG12C–EGFR Inhibition in Colorectal Cancer
27. Supplementary Figure 3 from Molecular Characterization of Acquired Resistance to KRASG12C–EGFR Inhibition in Colorectal Cancer
28. Supplementary Figure 4 from Molecular Characterization of Acquired Resistance to KRASG12C–EGFR Inhibition in Colorectal Cancer
29. Supplementary Figure 5 from Molecular Characterization of Acquired Resistance to KRASG12C–EGFR Inhibition in Colorectal Cancer
30. Supplementary Figure 1 from Molecular Characterization of Acquired Resistance to KRASG12C–EGFR Inhibition in Colorectal Cancer
31. Supplementary Figure 2 from Molecular Characterization of Acquired Resistance to KRASG12C–EGFR Inhibition in Colorectal Cancer
32. Angiogenesis Impairment in Id-Deficient Mice Cooperates with an Hsp90 Inhibitor to Completely Suppress HER2/Neu-Dependent Breast Tumors
33. Phenformin Enhances the Efficacy of ERK Inhibition in NF1-Mutant Melanoma
34. Author Correction: Selective inhibitors of mTORC1 activate 4EBP1 and suppress tumor growth
35. Heat Shock Protein 90 Mediates Macrophage Activation by Taxol and Bacterial Lipopolysaccharide
36. Farnesyl Transferase Inhibitors Cause Enhanced Mitotic Sensitivity to Taxol and Epothilones
37. Abstract 2: Vertical MAPK pathway targeting in novel genetically engineered mouse and cell line models of NF1-altered melanoma: the mSK-Mel murine cohort
38. Supplementary Table 3 from Molecular Characterization of Acquired Resistance to KRASG12C–EGFR Inhibition in Colorectal Cancer
39. Abstract 3882: tumor adaptations to PI3K inhibition increases and its reversibility decreases as a function of time in drug
40. Data from Impaired Proteolysis of Noncanonical RAS Proteins Drives Clonal Hematopoietic Transformation
41. Data from Molecular Characterization of Acquired Resistance to KRASG12C–EGFR Inhibition in Colorectal Cancer
42. Supplementary Figure from Impaired Proteolysis of Noncanonical RAS Proteins Drives Clonal Hematopoietic Transformation
43. Data from Combined EGFR/MEK Inhibition Prevents the Emergence of Resistance in EGFR-Mutant Lung Cancer
44. Data from Diverse and Targetable Kinase Alterations Drive Histiocytic Neoplasms
45. Supplementary Figure 7 from Combined EGFR/MEK Inhibition Prevents the Emergence of Resistance in EGFR-Mutant Lung Cancer
46. Supplementary Figure S5 from Relief of Feedback Inhibition of HER3 Transcription by RAF and MEK Inhibitors Attenuates Their Antitumor Effects in BRAF-Mutant Thyroid Carcinomas
47. Supplementary Table 2 from Prospective Blinded Study of BRAFV600E Mutation Detection in Cell-Free DNA of Patients with Systemic Histiocytic Disorders
48. Data from V211D Mutation in MEK1 Causes Resistance to MEK Inhibitors in Colon Cancer
49. Supplementary Figure 3 from EGFR Blockade Reverts Resistance to KRASG12C Inhibition in Colorectal Cancer
50. Data from mTOR Kinase Inhibition Causes Feedback-Dependent Biphasic Regulation of AKT Signaling
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.